PTGX: Ascending Triangle detected on 20 Mar 2026

PTGX forms an ascending triangle with perfect structure (15.0/15) and strong breakout mechanics (13.0/13), though volume is moderate at 9.6/12. Price at $101.68 sits just 0.14% below resistance of $101.50, with support at $95.30 providing a 6.38-point cushion. Overall score of 81.6/98 reflects high pattern quality. The stock has rallied 22.52% in one month and 156.77% from the 52-week low, indicating sustained uptrend continuation. RSI at 68.96 suggests near-term strength without overbought extremes, while volume ratio of 2.28x shows elevated participation.

Protagonist Therapeutics recently received U.S. FDA approval for ICOTYDE (icotrokinra) to treat adults with moderate to severe plaque psoriasis on March 18, 2026. This regulatory catalyst is major: the approval triggers a $50 million milestone to Protagonist; the company is eligible for 6–10% royalties and up to $580 million additional milestones. Jefferies on March 18, 2026 maintained a Buy rating and raised its price target to $121. Additionally, Citigroup raised its price target from $115.00 to $125.00 on Thursday. Takeda and Protagonist announced the FDA accepted the NDA for rusfertide and granted Priority Review with a PDUFA target action date in the third quarter of this calendar year. Analyst consensus is constructive, with 13 firms averaging a $112.25 price target. The stock closed at $101.68, placing it 3.79% below the 52-week high, suggesting pattern formation post-major approval news.

On a breakout above $101.50 resistance, the ascending triangle pattern projects a measured move target of $107.93 (conservative estimate), implying 6.2% upside from current levels. The pattern win probability of 62.93% indicates favorable historical odds. Volume confirmation would require sustain above the 2.28x volume ratio already present. The invalidation level sits at key support of $95.30—a close below this price would signal pattern failure. Successful breakout would target analyst price objectives ranging from $106 to $125, with intermediate resistance likely near the 52-week high of $105.47.

The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.53), and had revenue of $7.44 million during the quarter, compared to analysts' expectations of $14.92 million. Revenue upside depends on J&J's launch execution, uptake vs. large biologics, and the pace of royalty-bearing sales; most future payouts are contingent milestones. Also remember Protagonist previously reported a quarterly EPS miss, so profitability hinges on these partnership revenues scaling. The Health Care sector regime is bearish (-0.33), creating headwinds. RSI at 68.96 edges toward overbought territory, leaving limited upside cushion before technical exhaustion. Beta of 0.18 is extremely low, meaning this stock moves independently of broader market rallies—sector weakness could isolate the upside. Biotech valuations remain under pressure despite recent catalyst.